3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Classical hematology
1
CNS
1
Breast
1
Conditions
Glioblastoma
380
Brain Neoplasms
376
Glioma
232
Gliosarcoma
147
Astrocytoma
138
Neuroblastoma
121
Central Nervous System Neoplasms
118
Oligodendroglioma
80
Medulloblastoma
61
Breast Neoplasms
52
Neoplasms
51
Melanoma
45
Ependymoma
43
Carcinoma, Non-Small-Cell Lung
42
Recurrence
40
Sarcoma
33
Meningioma
33
Rhabdomyosarcoma
32
Neurofibromatosis 1
32
Osteosarcoma
31
Neoplasm Metastasis
29
Lymphoma, Non-Hodgkin
27
Wilms Tumor
26
Lung Neoplasms
26
Neuroectodermal Tumors, Primitive, Peripheral
25
Sarcoma, Ewing
23
Lymphoma
22
Rhabdoid Tumor
20
Hepatoblastoma
19
Testicular Neoplasms
17
Interventions
Temozolomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Neoplasms, Second Primary
×
CNS
×
Clear all
NCT00638963
2017-06-14
STOP
Merck Sharp & Dohme LLC
Phase 2
Terminated
6 enrolled
9 charts